Objectives
To evaluate the clinical efficacy and safety of tocilizumab and anakinra among hospitalized adults with laboratory-confirmed covid-19 at high risk of deterioration. At the suggestion of the Karolinska COVID-19 Treatment Working Group, we designed a randomized controlled trial comparing anakinra or tocilizumab versus usual care.